Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain

por Santiago Moreno Guillén, Juan Emilio Losa García, Juan Berenguer Berenguer, José Manuel Martínez Sesmero, Santiago Cenoz Gomis, Ruth Graefehain, David López Sánchez-Cambronero, Francisco Javier Parrondo García
Publicado en Farmacia Hospitalaria (2017)